Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Rectal Neoplasms 1Rare Diseases 1Oligodendroglioma 1Insulinoma 1Glucagonoma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Leucovorin 4Everolimus 4Fluorouracil 3Bevacizumab 3vatalanib 2pentetreotide 2Trastuzumab 2Sunitinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Cisplatin 2Bortezomib 2Biological Therapy 2veliparib 1tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Somatostatinoma × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡